Table 5.
Value of PET/CT scanning to assess a residual mass after completion of planned chemotherapy for Hodgkin lymphoma (HL) and aggressive nonHodgkin lymphoma (NHL)
PFS indicates progression-free survival; nr, not reported.
*63 of 66 patients with a positive scan received subsequent radiation.
